Comerica Bank Sells 9,639 Shares of IDEXX Laboratories, Inc. $IDXX

Comerica Bank lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 35.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,493 shares of the company’s stock after selling 9,639 shares during the quarter. Comerica Bank’s holdings in IDEXX Laboratories were worth $11,835,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in IDEXX Laboratories by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock valued at $6,364,638,000 after purchasing an additional 86,040 shares during the period. Bank of New York Mellon Corp grew its stake in IDEXX Laboratories by 41.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after purchasing an additional 605,290 shares during the period. Invesco Ltd. grew its stake in IDEXX Laboratories by 14.0% in the 3rd quarter. Invesco Ltd. now owns 1,320,263 shares of the company’s stock valued at $843,503,000 after purchasing an additional 161,782 shares during the period. Principal Financial Group Inc. grew its stake in IDEXX Laboratories by 16.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after purchasing an additional 187,967 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in IDEXX Laboratories by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after purchasing an additional 326,348 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on IDXX shares. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday. UBS Group dropped their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday. Piper Sandler dropped their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Finally, BTIG Research dropped their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Stock Down 1.2%

Shares of NASDAQ IDXX opened at $568.30 on Wednesday. IDEXX Laboratories, Inc. has a one year low of $428.09 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The business’s fifty day moving average price is $592.57 and its 200-day moving average price is $652.43. The stock has a market capitalization of $45.14 billion, a PE ratio of 43.48, a P/E/G ratio of 3.49 and a beta of 1.72.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $3.08 EPS for the quarter, beating analysts’ consensus estimates of $2.93 by $0.15. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.54 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP George Fennell sold 11,345 shares of the stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the sale, the executive vice president owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director directly owned 648 shares in the company, valued at $407,345.76. This trade represents a 69.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,957 shares of company stock worth $29,862,109 in the last three months. 0.79% of the stock is currently owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.